Written by admin October 15, 2024 Press Release Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes 1 min read Read More
Written by admin June 14, 2024 Press Release Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D. 1 min read Read More
Written by admin January 4, 2024 Press Release Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes. 1 min read Read More
Written by admin October 26, 2023 Press Release Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA. 1 min read Read More
Written by admin September 28, 2023 Press Release Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD. 1 min read Read More
Written by admin September 20, 2023 Press Release Seraxis announces closing of second VC tranche and successful completion of preclinical studies of pancreatic organoids from Seraxis’ novel pancreas-derived stem cells. 1 min read Read More
Written by admin July 16, 2023 Press Release Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia. 1 min read Read More
Written by admin April 25, 2023 Press Release Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit. 1 min read Read More
Written by admin August 30, 2022 Press Release Seraxis announces Appointment of Chief Medical Officer, Dr. Paul Strumph. 1 min read Read More
Written by admin February 9, 2021 Press Release Seraxis Announced Closing of $40M Series C Financing Round. 1 min read Read More
Written by admin November 12, 2018 Press Release Seraxis Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy. 1 min read Read More
Written by admin September 5, 2018 Press Release Seraxis Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents. 1 min read Read More
